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Summary 
 
1 Motivation 
In ancient times, diabetes was described as literally the flow through of urine and was further 
stratified as either diabetes insipidus (urine tasted insipid) or mellitus (urine tasted like honey) 
(Karamanou, et al., 2016; Qureshi, et al., 2014). Moving centuries forward (i.e., 1920s), the 
landmark discovery by Banting and Best (Banting, et al., 1922) that insulin regulated glucose 
and was produced in the endocrine pancreas set the stage for the treatment of diabetes 
mellitus. Today we recognize multiple forms of diabetes mellitus, with type 1 diabetes (T1D) 
and type 2 diabetes (T2D) forming the majority of cases (Kharroubi and Darwish, 2015). There 
are also multiple other types, including those that are now termed monogenic forms or where 
diabetes occurs as part of a syndrome, that are beyond the scope of this thesis (Kharroubi and 
Darwish, 2015) . 
The diabetes nomenclature has undergone several iterations with idiopathic, juvenile, 
adult, non-insulin requiring and insulin-dependent all being qualifiers in the classification of 
either what we today call T1D or T2D. We now understand that T1D is autoimmune in nature 
and our knowledge base has rapidly expanded (Atkinson, et al., 2014). Nonetheless critical 
knowledge voids exist in research efforts for this disease and we have yet to fully comprehend 
the etiology let alone find a cure for this disorder. Much of this knowledge has arisen from both 
human studies and animal models of T1D. The community has been fortunate to have 
spontaneous models of disease such as the Non Obese Diabetic (NOD) mouse (Anderson 
and Bluestone, 2005). This is somewhat unique to T1D as most other autoimmune conditions 
require induced models of disease for experimentation (Yu, et al., 2015). There are, however, 
many caveats to these models, and a rich literature exists with both detractors and supporters 
of this particular mouse model (Leiter and von Herrath, 2004; Roep and Atkinson, 2004). Much 
of this debate centers on the success in preventing and reversing T1D in the NOD mouse 
(Bowman, et al., 1994; Roep, et al., 2004; Shoda, et al., 2005) while disappointingly, such 
efforts have not translated into therapeutic efficacy for human T1D (Greenbaum and Atkinson, 
2011; Haller, et al., 2010; Herold and Bluestone, 2011; Herold, et al., 2013; Staeva, et al., 
2013; van Belle, et al., 2011). This translational inefficiency is not limited to T1D research, with 
calls for reproducibility and rigor in animal models of human diseases increasing (Landis, et 
al., 2012). Some of our own efforts have, however, yielded progress in this regard (Gill, et al., 
2016), yet it is most important to note that even under the best of circumstances, animal models 
will obviously not fully replicate all aspects of the human disease. 
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In terms of human T1D, researchers are to a large extent handicapped by the need for 
non-invasive research techniques since the pancreas, as the target organ, is not amenable to 
biopsy. This said, there have been autopsy materials studied (Foulis and Stewart, 1984; Gepts, 
1965; Willcox, et al., 2009) and some work on biopsies (Imagawa, et al., 1999; Krogvold, et 
al., 2014), but neither of these are widely used anymore for logistical and ethical reasons. This 
then forms the motivation of my work to study human tissue taking advantage of the JDRF 
sponsored Network for Pancreatic Organ donors with Diabetes (nPOD) program. This effort 
was established to obtain transplant grade human tissue for research (Campbell-Thompson, 
et al., 2012a). Specifically, we contracted with organ procurement organizations (OPO) 
throughout the United States to obtain tissue from donors with T1D, those that were T1D 
associated autoantibody positive without diabetes, and those without diabetes. As this program 
evolved, donors with T2D, cystic fibrosis, pregnancy and other cases were obtained as 
additional controls or as interests arose (www.jdrfnpod.org). The tissues procured include 
pancreas, pancreatic draining lymph nodes, mesenteric lymph nodes, spleen, thymus, bone 
marrow and peripheral blood (for isolation of both leucocytes and serum), wherever possible. 
These organs are shipped under specialized conditions to maximize viability and integrity. 
Once received, standard operating procedure (SOP) protocols are applied (Figure1.1-1) 
(Campbell-Thompson, et al., 2012c; Campbell-Thompson, et al., 2012d).  
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This ensures high quality samples for live cell analysis, standard histology, 
immunohistochemistry, immunofluorescence and downstream “omic” analyses (Kusmartseva, 
et al., 2017; Philips, et al., 2017; Pugliese, et al., 2014; Wasserfall, et al., 2016). 
 
Figure 1.1-1. Organizational chart of nPOD operations. Organ procurement organizations 
offer the nPOD organ-processing center cases. Screening laboratories around the United 
States while testing for HLA and infectious diseases also screen under 30 year old donors for 
T1D associated autoantibodies. Positive autoantibody donors are then offered as cases to the 
nPOD program. Cases obtained are then processed by nPOD, with standard operating 
procedures and quality control processes in place as indicated in the chart. 
 
In order to obtain at risk pre-T1D donors, we had to establish a network of screening 
laboratories to capture this population across the United States. A pilot effort (2005) had been 
undertaken (Gianani, et al., 2006) using the gold standard radioimmunoassay (RIA) for T1D 
associated autoantibodies.  However, it became clear in 2006 with nationwide roll-out that this 
would not be feasible in laboratories that are not set up to handle radioactivity. This led me to 
pursue an enzyme linked immuno-sorbant assay (ELISA) for these autoantibodies; this, for the 
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purpose of both validation and implementation of an SOP based protocol (Wasserfall, et al., 
2016), [CW 1].   
To date, we have screened over 6,000 samples from organ donors and procured 32 
autoantibody positive cases from individuals without T1D into the nPOD program. nPOD has 
also acquired 174 controls, 151 T1D, 41 T2D and 41 miscellaneous (pregnancy, monogenic 
diabetes, cystic fibrosis, etc.) cases. The nPOD group is set up as collaborative project and 
open to the T1D research community, which has led to approximately 170 publications using 
this sample resource. With these valuable tissues in hand, we have been able to address a 
number of long standing dogmas and ideas regarding human T1D. One of these notions is is 
in regard to insulitis and the immune attack on β-cells. This is well characterized in the NOD 
mouse model (Anderson and Bluestone, 2005) but remains elusive in human T1D (In't Veld, 
2011; In't Veld, 2014). Much of the previous work on this lesion has been derived from autopsy 
material, pancreatic biopsies or isolated islets (Dotta, et al., 2007; Foulis and Stewart, 1984; 
Gepts, 1965; Graham, et al., 2012; In't Veld, 2011; In't Veld, 2014; Kent, et al., 2017; Krogvold, 
et al., 2014; Richardson, et al., 2014). We therefore undertook a more comprehensive study 
of human insulitis within the nPOD collection. Of note and to our advantage, we have: a) the 
whole pancreas, b) donors covering the natural history from higher-risk (i.e., autoantibody 
positive) through onset, and c) into established disease. Thus, we were able to not only 
evaluate potentially pre-diabetes pancreatic tissue but also, address issues surrounding 
disease duration in terms of insulitis, as well as characterization of the infiltrates. Furthermore, 
with immunostaining, we were able to enumerate α- and β-cell mass (Campbell-Thompson, et 
al., 2016a) [CW 2].  
Given the relative differences in T1D infiltrates between humans and rodent models, 
we questioned afresh the presumed role of autoantibodies in the disorder’s pathogenesis. It is 
well established that autoantibodies are excellent biomarkers of T1D either in diagnosis or in 
prediction of future disease (Kupila, et al., 2001; LaGasse, et al., 2002; Pinhas-Hamiel, et al., 
1998; Schatz, et al., 1994; Siljander, et al., 2007). There are autoantibody mediated diseases 
such as Grave’s disease where transplacental passage of IgG autoantibodies transfer 
transient hypo- or hyperthyroidism (Brown, 1996) as an example, and while transplacental 
passage of T1D associated autoantibodies has been documented, this does not appear to 
impact β-cell function (Hamalainen, et al., 2001; Ziegler, et al., 1993). The traditional role of 
antibodies in the immune system is in the neutralization of toxins and viruses as well as the 
opsonization of bacteria and protozoans; however, by activation of: a) the classical 
complement pathway; or b) natural killer (NK) cell mediated antibody dependent cellular 
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cytotoxicity (ADCC), cells may be killed by antibody driven events. Taken together, while 
evidence for autoantibody initiation of T1D is lacking, it may still be possible that participation 
in ongoing pathology occurs. There is at least one report of NK cell involvement by in situ 
staining for these cells in recent onset disease (Dotta, et al., 2007). We decided, however, to 
investigate the role that complement may have in T1D as an alternative hypothesis for 
autoantibody involvement in T1D progression (Rowe, et al., 2013) [CW-3]. 
 Another longstanding dogma of T1D is that the clinical diagnosis of disease is made 
when hyperglycemia occurs because the functional β-cell mass has declined to a point where 
about 10-20% is left, and this continues to absolute loss of these cells (Figure 1.1-2). 
Therefore, the islets are insulin deficient and insulinopenia follows with progressive loss of C-
peptide (a marker of endogenous insulin production) (Eisenbarth, 1986). While this has come 
under challenge and subject to modification in recent years, we were motivated to use the 
nPOD samples to investigate the endocrine pancreas, in particular the pathways of mature 
insulin production from the proinsulin molecule using immunostaining, protein extraction and 
gene expression studies (Wasserfall, et al., 2017) [CW 4].  
 
 
Figure 1.1-2. Model of progression to T1D.  This model describes T1D as the progressive 
loss of beta cells following genetic and environmental events that initiate an autoimmune 
attack. It proposes the absolute loss of beta cells to occur in T1D. (From Eisenbarth, GS, NEJM 
1986)  
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2 State of the Art 
 
2.1 Type 1 diabetes is an autoimmune disease 
 
The two major forms of diabetes account for about 5-10% (T1D) and 80-90% (T2D) of cases, 
respectively(Kharroubi and Darwish, 2015) . T1D is absolutely insulin requiring to sustain not 
only blood glucose levels but also life (Atkinson, et al., 2014). The next major event in the effort 
to understand etiopathogenesis was the discovery of leukocytic infiltration into the insulin 
producing β-cells in the islets of Langerhans within the pancreas of individuals who died at the 
onset of disease (Gepts, 1965). Shortly thereafter, the discovery of islet cell autoantibodies 
(ICA) (Bottazzo, et al., 1974) and then, the association with the human leucocyte antigen (HLA) 
complex (Cahill and McDevitt, 1981) set the stage for ultimately ascribing an autoimmune 
etiology for T1D. Subsequently, the establishment of T1D as an autoimmune disease has been 
corroborated by a large number of studies through the present and in part, is described in the 
following sections 2.2 through 2.6. Nonetheless, there is also a growing body of evidence to 
suggest that the end organ, in this case the β-cells of the islets, may also contribute to their 
own demise (Atkinson, et al., 2011; Bottazzo, 1986; Bottazzo, et al., 1988), and this is further 
discussed in section 2.5. 
 
2.2 Models of type 1 diabetes 
 
Contemporaneously to the initial findings in humans, several animal models emerged that 
allowed for experimentation not possible in humans. Some of these models are induced by β-
cell toxicity (streptozotocin or alloxan, for example) (Yoon, et al., 1987); however, these 
replicate the loss of insulin but not necessarily the autoimmune nature of T1D. Others for 
example, the viral antigen induced model (von Herrath, 2002), are models of immune attack 
of the β-cells. Spontaneous models, such as the Bio-Breeding Diabetes-Prone (BBDP) rat 
(Yale and Marliss, 1984) and the aforementioned NOD mouse (Anderson and Bluestone, 
2005), have made up the majority of the knowledge base about animal T1D and have been 
extensively studied (Lenzen, 2017). As discussed earlier, there are caveats and concerns 
regarding animal models (Landis, et al., 2012; Leiter and von Herrath, 2004; Roep and 
Atkinson, 2004); however, the NOD mouse in particular has served as a guide to dissect 
human T1D. In the NOD, autoantibodies to insulin predominate; T-lymphocytes cause 
destruction of β-cells; T-lymphocytes can transfer T1D into a recipient immune deficient NOD 
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animal; the major histocompatibility complex (MHC) is critical; insulitis begins early and leads 
to complete loss of insulin production; and a number of immune defects in regulation exist in 
this model (reviewed in (Anderson and Bluestone, 2005)). So collectively and with a critical 
appraisal of this model, wherein genetic manipulation can test hypotheses, we can also use 
this as a roadmap to address human T1D.  Ultimately though, human studies have to be 
undertaken to understand clinical T1D. 
 
2.3 Humoral immune responses in human type 1 diabetes 
 
The landmark discovery of ICA (Bottazzo, et al., 1974) led to a search for the nature of the 
autoantigens that comprise the ICA reaction. This largely followed on from increased 
understanding of both physiology and technological advancements in assay design. Since 
radiolabelled insulin existed (Yalow and Berson, 1960) for competitive measurement of insulin, 
a reagent like this was used to detect autoantibodies in humans with T1D prior to the treatment 
with insulin (Palmer, et al., 1983). These insulin autoantibodies (IAA) along with ICA were the 
first to be used in both diagnosis and prediction of T1D and set the stage for some of the largest 
T1D prevention studies ever undertaken (Schatz and Bingley, 2001) While this was occurring, 
the search for other autoantigens continued, and these too were subsequently used in 
prediction studies (discussed in 2.6 below). The use of radioactively labeled methionine in 
pulse chase experiments with isolated β-cells followed by immunoprecipitation of the 
radiolabelled extracts with human T1D sera led to identification of autoantibodies initially called 
by their molecular weights (e.g., 64k, 40k or 37k) on gel electrophoresis (Atkinson and 
Maclaren, 1988; Christie, et al., 1990; Christie, et al., 1994; Gerling, et al., 1986; LaGasse, et 
al., 1997). The 64kD autoantigen was subsequently identified as glutamic acid decarboxylase 
(GAD) (Baekkeskov, et al., 1990), and the autoantibody (GADA) was found to be another 
effective marker for T1D. Phage display library approaches discovered ICA512 (Rabin, et al., 
1994), while an insulinoma mRNA subtraction approach identified insulinoma associated-2 (IA-
2) (Lan, et al., 1996) as autoantigens, and the autoantibody is commonly referred to as IA-2A. 
Upon sequencing these two autoantigens it turned out that not only were these two molecules 
identical, but as fragments, they were also related to the aforementioned 40kD and 37kD 
autoantigens (Bonifacio, et al., 1995; Payton, et al., 1995). Using an array coupled with a 
bioinformatics type approach, zinc transporter 8 autoantibodies (ZnT8A) were found to be 
present in sera from T1D subjects (Wenzlau, et al., 2007). The aforementioned molecules are 
considered the major targets of autoantibodies and are currently the ones used in 
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epidemiological studies. The specificities for these when comparing new onset T1D to control 
subjects are typically in the range of 95-99% while sensitivities are approximately 50% for IAA, 
70-80% for GADA, 60-70% for both IA-2A and ZnT8A (Bingley, et al., 2003; Bingley and 
Williams, 2013; Bingley, et al., 2010; Lampasona, et al., 2011; Miao, et al., 2013; Xie, et al., 
1997). However, there certainly have been a number of other autoantigens identified and 
probably more remain to be discovered (Mansson, et al., 2001; Roep and Peakman, 2012; 
Winter and Schatz, 2011). These, however, typically have lower than 40% sensitivity and are 
not usually included in standard screening or diagnostic applications. 
 Antibody mediated effector functions (Quast, et al., 2017; Valenzuela and Reed, 2017) 
include neutralization of toxins and viruses, opsonization of bacteria and protozoans for 
phagocytosis (Lu, et al., 2017), complement fixation for killing of cells (Shokal and 
Eleftherianos, 2017) and NK cell mediated ADCC. Another possibility is for antibodies to 
behave as either an agonist or antagonist as for anti-thyroid stimulating receptor 
autoantibodies (Brown, 1996). The potential pathogenic role of autoantibodies in T1D is 
unresolved, and the question remains: are they simply markers of ongoing autoimmunity or do 
they have a pathological significance beyond the potential role of B-lymphocytes, which not 
only produce antibodies but also can present antigen (Ilonen, et al., 2007; Knip and Siljander, 
2016)? 
 These humoral responses to insulin, GAD and IA-2 have been shown to be of the IgM 
or IgG classes, with additional subclasses of IgG (Fuchtenbusch, et al., 2000; Hawa, et al., 
2000; Hillman, et al., 2009; Hoppu, et al., 2004a; Hoppu, et al., 2004b; Ng, et al., 2002; Oak, 
et al., 2011; Omar, et al., 1987; Piquer, et al., 2005; Ronkainen, et al., 2006). This argues for 
B-lymphocyte class switching and hence, for a thymic dependent antigen (den Haan, et al., 
2014). Collectively, this is a demonstration of an immune response to these autoantigens. In 
order for this response to occur, these autoantigens have to be presented to the effector cells 
of the immune response by antigen presenting cells (APC). Furthermore, CD4+ T cell help is 
required for the class switching aspect, and this cell-mediated response is discussed in section 
2.4 (den Haan, et al., 2014). 
 
2.4 Genetics and cell mediated immunity in human type 1 diabetes 
 
Similar to the autoantibody discoveries, the role of cellular immune responses followed 
technological innovations along with insights and progress into unraveling mechanisms of the 
overall immune response. In terms of T1D, firstly, the descriptions of cellular infiltrates into the 
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islets of langerhans essentially laid the foundation of cellular immune responses being involved 
in T1D (Foulis and Stewart, 1984; Gepts, 1965; Karamanou, et al., 2016). Secondly, the 
association of the MHC or HLA with T1D (Cahill and McDevitt, 1981) and the discovery that 
this set of molecules dictates the presentation of antigen peptides to the immune system firmly 
cemented the relationship of cell-mediated immunity with this disorder (Doherty and 
Zinkernagel, 1975; Zinkernagel and Doherty, 1974a; Zinkernagel and Doherty, 1974b). It is 
known that in the thymus HLA class I restricts the immune response of CD8 positive T-
lymphocytes while HLA class II restricts the response of CD4 positive T-lymphocytes (Kondo, 
et al., 2017). Following this process of positive selection, the CD4+ or CD8+ T cells undergo a 
round of negative selection. This entails promiscuous self antigen presentation to these 
emerging T cells and the subsequent deletion of cells reacting to self, or in another pathway 
the development of T regulatory cells (Treg) (Kondo, et al., 2017). Outside of this central 
tolerance program there exist multiple ways in which tolerance occurs in the periphery. This 
so-called peripheral tolerance involves checkpoints in the immune response, cytokines and 
soluble mediators, peripherally induced Treg, apoptosis mechanisms and others (Danikowski, 
et al., 2017; Frydenlund and Mahalingam, 2017; Theofilopoulos, et al., 2017). 
 How then collectively do T cells arise that recognize β-cell specific antigens? Part of 
the answer lies in decades of work implicating failures in both central and peripheral tolerance 
mechanisms, yet the complete story has not been revealed. Why particular MHC alleles 
associate with risk from a functional standpoint is largely unknown and mostly speculative; 
however, a genetic region known as the insulin variable number of tandem repeats (VNTR) 
has been shown to modulate proinsulin expression in the thymus, potentially pointing to a 
failure in central tolerance as well as explaining some antigenic specificity for T1D (Pugliese, 
et al., 1997). Approximately 50 loci in the human genome appear to be associated with T1D 
(Cooper, et al., 2012; Onengut-Gumuscu, et al., 2015; Rich, et al., 2012), and these are largely 
found to be immune-centric, implying perhaps, amongst other things, peripheral tolerance 
defects in immune responses. However, the functional link of these putative loci to causation 
of T1D remains elusive.  
 The immune response culminates in an effector phase, and we classify these according 
to the pathway used. The entire immune response is usually involved in all responses, but it is 
the effector phase that leads to elimination of a foreign invader or in some instances, pathology 
to the host. For example Type 1 hypersensitivity is the IgE mediated release of mast cell 
contents leading to allergic responses (Reber, et al., 2017). In T1D, it is thought that Type IV 
(delayed hypersensitivity) effector CD8+ T-lymphocytes mediate responses that lead the death 
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of β-cells (Knight, et al., 2015; Zaldumbide, et al., 2013). Unlike B-lymphocytes, which produce 
antibodies that recognize whole protein in native configuration, T-lymphocytes recognize small 
peptides presented by MHC. As described earlier, CD8+ T-lymphocytes are restricted by MHC 
class I, while the major risk allele in T1D is MHC class II which implicates CD4+ T-lymphocytes. 
The role of CD4+ T-lymphocytes in providing signals to B-lymphocytes to effect class switching 
(den Haan, et al., 2014) is one possibility, or it is possible that CD4+ T-lymphocytes produce 
cytokines (Amrani, et al., 2000; Calderon, et al., 2006; Padgett, et al., 2013) that are toxic to 
β-cells. The evidence for these as well as CD8+ T-lymphocytes is discussed in the following 
section 2.5. 
 The vast majority of studies on human cell mediated immunity in T1D have been 
conducted on peripheral blood leukocytes. This has proven much more challenging than the 
autoantibody assays. The parallels to these efforts include development of blinded workshops 
for T-lymphocyte assays (Brooks-Worrell, et al., 2011; James, et al., 2011; Mallone, et al., 
2011a; Mallone, et al., 2011b), and while this has helped standardize aspects of these assays, 
they are still not as robust as the autoantibody assays. This limitation has been attributed to 
several reasons, one of which is that serum can be stored and shared much more readily than 
T-lymphocytes for workshops. However, more compelling is that a) the nature of the 
antigen/peptide is not known, and b) the frequency of these cells in the periphery is very low 
(Roep, 1996). Nonetheless, progress has been made in these directions, and with more 
modern approaches in assay technology, such as dye dilution assays, tetramer analyses, and 
cytokine secretion in response to autoantigen(s), have revealed specific T-lymphocytes in the 
peripheral blood of T1D patients (Mannering, et al., 2010). More recently, notions of altered 
peptide processing for presentation by APC have come to the fore, including post-translational 
modification (Mannering, et al., 2005), hybrid peptide formation (Delong, et al., 2016), and 
other means (Kracht, et al., 2017; McLaughlin, et al., 2016). 
 To date, several peptide antigens including hybrid peptides have been shown to either, 
stimulate or by tetramer staining, enumerate T-lymphocytes from T1D subjects, and they 
indeed are in low frequency in the periphery. The list includes but is not limited to, for CD4+ 
cells: preproinsulin, GAD65, GAD67, IA-2, phogrin, islet cell antigen 69, 38k antigen and heat 
shock protein 60; for CD8+ cells: GAD65, IA-2, islet amyloid polypeptide (IAPP) and islet-
specific glucose-6-phosphatase catalytic subunit-related protein (Roep and Peakman, 2012).  
 On the other side of these effector mechanisms is immunoregulation. This similarly has 
been the subject of intense research with some conflicting results. In particular, CD4+CD25+ 
Treg cells have either been found to be in reduced frequency (Brusko and Atkinson, 2007; 
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Tree, et al., 2006), reduced function (Garg, et al., 2012; Lindley, et al., 2005; McClymont, et 
al., 2011; Visperas and Vignali, 2016) or not different at all (Brusko, et al., 2007; Hamari, et al., 
2016), while others have found increased resistance of effector cells to immunoregulation 
(Schneider, et al., 2008), when comparing blood from controls and T1D subjects. Yet other 
studies have found B-lymphocyte regulation (Kleffel, et al., 2015), myeloid derived suppressor 
cell regulation (Whitfield-Larry, et al., 2014), checkpoint type defects (Andre, et al., 1996; Dai, 
et al., 2014; Paterson, et al., 2011) and other immunoregulatory issues (Fuhrman, et al., 2015; 
Roep and Tree, 2014) in T1D subjects.  
There are, as described, multiple lines of evidence for humoral and cellular immune 
events in the progression to T1D. Some of these have been documented or confirmed by using 
islets, biopsies, autopsies and organ donor tissue of pancreas and pancreatic draining lymph 
nodes, which will be discussed in the following section 2.5.  
 
2.5 The lesion in human type 1 diabetes 
 
Ultimately, the effector phase of this autoimmune response must take place in the pancreas 
with the killing of islet cells and in particular, β-cells. In fact, the remarkable precision of this 
process with α- and δ- cells being largely left unscathed is further evidence of a specific 
autoimmune event. While animal models have informed us of some of the events in the demise 
of β-cells, it has been controversial and perhaps sometimes misleading, as has been described 
earlier. The number of T1D human pancreas cases examined is astonishingly small, relatively 
speaking. However, between earlier autopsy (Foulis and Stewart, 1984; Gepts, 1965), limited 
biopsy (Imagawa, et al., 1999; Krogvold, et al., 2014), islet isolation (Kent, et al., 2017) and 
organ donor (Campbell-Thompson, et al., 2012a; Gianani, et al., 2006) efforts, there is 
sufficient number to begin addressing events in the actual lesion of T1D. 
Collectively, these results have yielded that in general, insulitis occurs in younger 
donors, closer to onset of disease, and in those with multiple autoantibodies (Foulis, et al., 
1986; Gianani, et al., 2006; In't Veld, 2011; In't Veld, et al., 2007; Krogvold, et al., 2014; Wiberg, 
et al., 2015). The nature of this insulitis has been addressed a few different ways. By tetramer 
staining of pancreas from nPOD cases (Coppieters, et al., 2012) at the inception of the 
program, it was discovered that CD8 positive cells specific for insulin, IGRP and IA-2 could be 
found in distinct islets from individuals with T1D. Along with the CD8 positivity, this group also 
demonstrated MHC class I as being highly expressed on islets in T1D pancreata, which 
suggests that these infiltrates are in all likelihood, effector cells killing β-cells. This finding of 
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MHC class I increased expression in T1D pancreas has been replicated in other studies 
(Richardson, et al., 2016) while yet others dispute this finding (Skog, et al., 2015). The reason 
for increased expression of MHC class I on islets is unresolved, and it is speculated that a 
virus (Rodriguez-Calvo, et al., 2016) or elements of the viral response pathway may initiate 
this response (Newby, et al., 2017; Newby and Mathews, 2017). Another way this has been 
interrogated is by cloning T cells out of islets isolated from T1D donors (Kent, et al., 2017; 
Pathiraja, et al., 2015). The advantage of this approach is the ability to then perform live cell 
assays (Newby, et al., 2017) by growing these clones of cells. The antigen specific receptors 
on these cells can also be sequenced (Michels, et al., 2017) and then, for example, the T cell 
receptor (TCR) can transgenically be recreated for additional experiments (Babad, et al., 2015; 
Sprouse, et al., 2016). APCs, CD4+ or CD8+ T cells may also produce cytotoxic cytokines and 
contributing to β-cell dysfunction/loss in this manner (Eizirik, et al., 2012). 
 The presence of insulitis, while not near the intensity of that found in animal models, 
begs the question of what functional/effector pressure is exerted on the β-cell? Included in this 
equation then also is the question of how the milieu and β-cell contribute to the overall outcome 
of loss of insulin leading to loss of glucose homeostasis? 
 The primary function of β-cells is to react to an increase in blood glucose (Jouvet and 
Estall, 2017). This is achieved by integrating actual glucose levels by receptor-mediated events 
along with incretin signals from the gut and neuronal signals from the brain (Hussain, et al., 
2016). An increase in ATP from glucose metabolism in the cytosol of the β-cell allows 
potassium channels to open, and along with calcium influx, this leads to exocytosis of granules 
with stored insulin, C-peptide and IAPP secreted into circulation (Yang, et al., 2014). This 
allows rapid release of insulin followed by a period of replenishing these molecules. Proinsulin 
and pro-IAPP, once translated from mRNA on ribosomes, are passaged through the 
endoplasmic reticulum and are then both processed by the Proprotein Convertase 
Subtilisin/Kexin Type 1 (PCSK1) and Proprotein Convertase Subtilisin/Kexin Type 2 (PCSK2) 
enzymes into insulin and C-peptide from proinsuilin and IAPP from ProIAPP (Figure 2.5-1 (A)). 
The enzyme carboxypeptidase E (CPE) then cleans up lysine and arginine residues on the 
ends of the mature insulin and IAPP molecules post convertase cleavage (Alarcon, et al., 2012; 
Hutton, 1994; Smeekens, et al., 1992; Steiner, 2011; Steiner, et al., 1969). Insulin and C-
peptide then are logically in equivalent molar amounts while IAPP is independently co-secreted 
with insulin. This is useful for us in that C-peptide is often measured as a surrogate for insulin 
in β-cell function assays, especially in T1D subjects, since the exogenous therapeutic 
recombinant insulin does not contain C-peptide (Steiner, 2011). In α-cells, proglucagon is 
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processed by only the PCSK2 and CPE enzymes to form mature glucagon (Figure 2.5-1 (B)). 
If PCSK1 is present, as in the L-cells of the intestine, proglucagon will be processed into 
glucagon like peptide 1, glicentin and oxyntomodulin (Figure 2.5-1 (C)) (Tucker, et al., 1996). 
Figure 2.5-1 Prohormone processing of (A) Proinsulin or ProIAPP to either insulin and C-
peptide or IAPP respectively in β cells. (B) Proglucagon into glucagon in α cells. (C) 
Proglugagon into glucagon like peptide 1, glicentin and oxyntomodulin in L cells. 
 
 In T2D, it is thought with increasing insulin resistance the output of the β-cells is greater 
than processing and this leads to increased proIAPP and proinsulin in circulation. ProIAPP 
acts as a nidus to attract IAPP with tangles of this protein then forming amyloid leading to 
further β-cell failure (Jaikaran and Clark, 2001; Montane, et al., 2012; Raleigh, et al., 2017). 
Stress in the endoplasmic reticulum has also been noted as a feature in T2D (Herbert and 
Laybutt, 2016; Liu, et al., 2007; Ozcan and Tabas, 2016; Wang, et al., 2016). Whether this is 
something that occurs in T1D is unclear but certainly is a concept getting increasing attention 
(Brozzi and Eizirik, 2016; Engin, 2016; Zhong, et al., 2012). This potentially creates a complex 
milieu of β-cell stress/dysfunction and autoimmunity collaborating to result in T1D 
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2.6 Prediction of type 1 diabetes in the general human population 
 
Since the discovery of autoantibodies (Bottazzo, et al., 1974) in T1D, decades of work have 
gone into using these markers as a means to predicting this disorder (Bonifacio, 2015). Starting 
with ICA (Bottazzo, et al., 1974) and IAA (Palmer, et al., 1983), these have been used to predict 
T1D in first-degree relatives as well as in the general population. As GADA (Baekkeskov, et 
al., 1990), IA-2A (Rabin, et al., 1994) and ZnT8A (Wenzlau, et al., 2007) were discovered, they 
too were used in prediction. As a number of cohorts have now been followed from birth to 
onset of T1D, various prediction strategies can be both prospectively and retroactively tested 
(Bonifacio, et al., 2004; Krischer, et al., 2017; Rewers, et al., 1996a; Rewers, et al., 1996b; 
Vehik, et al., 2016; Ziegler and Bonifacio, 2012). In general, seroconversion to autoantibody 
positivity usually occurs after maternal antibodies have waned at around 6 months of age 
(Stanley, et al., 2004; Ziegler, et al., 1993). The order in which these autoantibodies appear is 
IAA, then GADA, while IA-2A and ZnT8A are very specific and increase closer to onset 
(Bonifacio, 2015). However, this is a generalization and not always the case. The affinity titer 
and number of different autoantibodies also matter in terms of predicting future T1D. Here, 
increased titer (Bonifacio, et al., 1990), higher affinity (Achenbach, et al., 2004) and greater 
number (Ziegler, et al., 2013) of different specificities of autoantibodies serve to enhance the 
specificity of prediction at the cost of decreased sensitivity (Giannopoulou, et al., 2015). Using 
orthogonal assays usually also improves specificity (Bonifacio, 2015).  
 While 80-90% of individuals with an incident diagnosis of T1D do not have a family 
history of the disease, having a family member does elevate risk for disease (Bonifacio, 2015). 
This has led to the use of family cohorts to enrich study cohorts to find pre-diabetes subjects. 
Clearly there is genetic involvement, but this is of a polygenic nature and not that of simple 
Mendelian inheritance. As mentioned earlier, HLA has the highest predictive value genetically 
for T1D, and around 50 or more genomic polymorphisms have been identified to be associated 
with risk for this disease (Cooper, et al., 2012). While HLA is predominant in these risk 
assessments, it has been possible to mathematically weight the other genetic polymorphisms 
to devise and improve a risk score (Frohnert, et al., 2017; Oram, et al., 2016; Patel, et al., 
2016; Winkler, et al., 2014; Winkler, et al., 2012a).  
 It is worth mentioning that mutations in forkhead box P3 (FOXP3) (Verbsky and Chatila, 
2013) and autoimmune regulator (AIRE) (Bruserud, et al., 2016) while rare, are involved in 
tolerance induction and lead to T1D with high certainty along with multiple other 
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autoimmunities. These particular defects are part of syndromes and not part of this discussion.  
Secondly, environment clearly plays a part in T1D progression and maybe even initiation, but 
this has been difficult to pin down let alone use for prediction. The evidence is several fold: for 
example, concordance for T1D in identical twins was initially thought to be about 34% (Olmos, 
et al., 1988) but may reach 70% with sufficiently long follow-up (Redondo, et al., 2008), 
implying that environmental factors may effect rates of progression. Another example would 
be the different prevalence and incidence in neighboring countries such as Finland and Estonia 
(Tuomilehto, et al., 1991), which are genetically similar but differ in environment and 
socioeconomics, with the implication that environmental factors modulate T1D initiation and/or 
progression. Agents such as Vacor (Esposti, et al., 1996) that are β-cell toxic will also lead to 
insulinopenia although through toxicity without autoimmune involvement. These are all not 
commonly useful for prediction especially in sporadic T1D. Similarly, the increased use of 
checkpoint inhibitors in cancer immunotherapy has increased the risk of autoimmunity, 
including T1D, in subjects receiving this therapy, and this is useful to know in these particular 
instances but not a factor in prediction of regular autoimmune T1D (Yoest, 2017). 
 The use of T-lymphocytes in specific predictive assays has yet to yield efficacy in 
screening assays for future T1D. This is an area that is actively being researched with, for 
example, direct typing  and then imputation of the amino acid sequences of the TCR (Seay, et 
al., 2016) which may prove predictive of T1D in the future by finding these rare cells in the 
periphery. 
 On the metabolic side, factors like rising glycation of proteins such as hemoglobin alpha 
1 fraction c (HbA1c) levels and alterations β-cell function are specific but not sensitive for 
prediction of impending T1D (Vehik, et al., 2012). How best to incorporate these in to predictive 
scores would seem to be a composite score of oral glucose challenge test results with glucose 
and C-peptide levels (Greenbaum, et al., 2011; Sosenko, et al., 2015a; Sosenko, et al., 2015b). 
Ongoing work is suggestive of altered ratios of proinsulin to either insulin or C-peptide may 
precede the onset of T1D (Sims, et al., 2016; Van Dalem, et al., 2016). Markers of β-cell death 
such as a so-called liquid biopsy of serum measuring the ratio of demethylated to methylated 
insulin DNA may offer another marker once validated (Akirav, et al., 2011; Lehmann-Werman, 
et al., 2016). Additional serum markers are continuously being sought, and again a composite 
score of multiple serum markers (e.g., metabolomics, proteomics, etc.) may be beneficial in 
improving the prediction of future T1D (Overgaard, et al., 2016; von Toerne, et al., 2017). 
 The importance of predicting T1D lies in the eventual goal of preventing this disorder. 
Secondly it has also been shown that an awareness of potentially impending T1D has 
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improved timely diagnosis if and when the disease declares itself (Chan, et al., 2015; Winkler, 
et al., 2012b). While most of the work described above is within families with a T1D proband, 
for the most part, the same findings hold true for general population screening. The difference 
being the population prevalence is even lower than in families, and this adds to the difficulty in 
terms of positive predictive values. However, with a multiplicity of factors we can predict future 
T1D in the general population (Batstra, et al., 1997; Batstra, et al., 2001; Bingley, et al., 1993; 
Gianani, et al., 2006; Knip, et al., 1998; Knip, et al., 2010; Kupila, et al., 2001; LaGasse, et al., 
2002; Maclaren, et al., 2003; Schatz, et al., 1994; Ziegler, et al., 2013). We have used this 
collective understanding of prediction to attempt to find pre-diabetes in the general organ 
donor population. This is in order to obtain and study the pancreas of individuals who may be 
truly pre-T1D. This represents a challenge on several fronts but primarily, because the 
prevalence of T1D in the USA general population is 1:250 and since these are organ donors, 
we are looking at a cross-section without being able to monitor conversion to additional 
autoantibodies or metabolic changes to know if T1D would ever occur (Atkinson, et al., 2014). 
So we rely on the natural history studies, including those from the general population, in 
assessing risk. Currently, logistically the best we can use is HLA (used for tissue matching in 
transplant and hence available for organ donors), a screen for multiple autoantibodies and 
sometimes HbA1c (if available) to recover pancreata from organ donors at presumptive 
increased risk for T1D. Post hoc additional genetic scoring, perhaps histology and orthogonal 
autoantibody assays can be applied to confirm risk for T1D. Ultimately, we also hope that pre-
diabetes, T1D and control tissues obtained by the nPOD program can not only find targets for 
therapeutic intervention but also, provide information relevant to future risk assessments. 
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3 Objectives 
 
The study of human pancreas at various stages of the progression to T1D is the overall 
objective of this study. In order to achieve that, access to relevant tissues is required, as well 
as having appropriate protocols established to evaluate the hypothesis that T1D is 
autoimmune in nature but that the β-cells may contribute to their own demise. The following 
specific aims were used to achieve that goal. 
 
Specific Aims 
1. Establish a screening program to acquire human tissue from organ donors with type 
1 diabetes associated autoantibodies. 
The overall structure of the nPOD program (Fig 1-1), as originally planned, included the 
establishment of autoantibody screening in order to acquire pancreas from individual donors 
at risk for T1D, who do not have a diagnosis of hyperglycemia or diabetes.  
(1) I modified a commercially available ELISA to measure GADA, IA-2A and ZnT8A in 
three hours so that results would be available in a time frame suitable for decisions to 
be made about organ placement. 
(2) I set up and trained laboratories around the USA to cover a large pool of potential 
organ donors. 
(3) I implemented screening and quality control programs which we used to fine-tune the 
reporting and performance of the assay. 
(4) We acquired pancreas samples from donors that were controls without diabetes, 
autoantibody positive donors without diabetes, and those who had T1D or T2D. 
 
2. Evaluate the role of insulitis and complement in human type 1 diabetes. 
While the progression of insulitis is well characterized using animal models of disease this is 
less so in the case in human T1D. This aim addressed both the frequency/extent of insulitis 
throughout the natural history of T1D and the potential role of humoral immune responses in 
T1D. 
(1) We set up staining protocols to evaluate immune cell infiltrates in control, autoantibody 
positive without diabetes, and T1D organ donor pancreas samples. 
(2) We used standardized criteria from a pathology consensus manuscript. 
(3) Imunohistochemistry stains were used to quantify α-cell (glucagon) and β-cell (insulin) 
mass. 
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(4) Metadata associated with each case, such as age of disease onset, disease duration, 
number and type of autoantibodies, HLA and diabetic ketoacidosis (DKA) were 
correlated with insulitis or α- or β-cell mass. 
(5) We stained pancreas cryosections for complement component 4d (C4d) from control, 
autoantibody positive without diabetes, T1D and T2D donors. 
(6) We evaluated the C4d staining in the context of disease, HLA and autoantibody type 
and frequency. 
3. Address the loss of endocrine hormones in the pancreas of humans with type 1 
diabetes. 
(1) We stained human pancreas by both immunofluorescence and 
immunohistochemistry techniques for proinsulin, insulin and glucagon. 
(2) We performed in situ hybridization for insulin mRNA on cryosections of human 
pancreas. 
(3) We measured total protein, proinsulin, insulin, C-peptide, glucagon and IAPP 
following acid ethanol extractions of thick (3x50μm) pancreas cryosections. 
(4) We designed primers and performed real-time quantitative polymerase chain 
reaction (RT-qPCR) on extracted Ribonucleic Acid (RNA) from flash frozen pancreas 
blocks of tissue.  
(5) We analyzed and annotated immunostained pancreas tissue slides to semi- quantify 
the number of β-cells in islets and in isolated clusters or single cells in the whole 
section. 
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4 Own Research 
 
4.1 Screening organ donors for type 1 diabetes autoantibodies is feasible. 
 
The nPOD program, as previously described (Campbell-Thompson, et al., 2012a; Pugliese, et 
al., 2014), was set up to obtain human tissue from organ donors with T1D, those at risk for 
T1D, and matched controls. The goals of my effort were to specifically optimize and implement 
the autoantibody-screening (Wasserfall, et al., 2016) [CW1] program to find organ donors at 
risk for T1D. The logistics of this program entailed a) finding screening partners and b) 
choosing an assay format that could be widely used. The screening partners that made most 
sense were laboratories already screening serological samples from OPOs; however, this 
decision eliminated the gold standard radioimmunoassay for autoantibodies (Bingley, et al., 
2003; Bingley and Williams, 2013; Bonifacio, et al., 1988; Brooking, et al., 2003; Gianani, et 
al., 1995). I therefore tested at that time a newly available ELISA for GADA (Brooking, et al., 
2003) and IA-2A (Chen, et al., 2005) autoantibodies and then, subsequently ZnT8A 
(Petruzelkova, et al., 2014). We used Receiver Operating Characteristic (ROC) analysis to set 
cutoffs for each ELISA that were highly specific (Fig 1 [CW1]). This was done for reasons of 
reducing false positives so as to maximize nPOD resources and to avoid potentially removing 
organs from the transplant pool.  
 With these assays established, we transferred the technology to OPO screening 
laboratories across the United States of America. As the program grew, we made adjustments 
to these assays and training procedures, and as shown in (Fig 2 [CW1]), we improved 
concordance with the ELISA and the gold standard RIA along with increasing the number of 
individuals screened. We reported this effort in 2016, but the program continues and thus far 
as of 2017, we have screened approximately 6000 samples and have 32 confirmed 
autoantibody positive donors. 
 An important aspect of this effort is one of quality control. We have entered these ELISA 
assays into the Diabetes Autoantibody Standardization program (DASP) (Bingley, et al., 2003), 
subsequently renamed Islet Autoantibody Standardization Program (IASP) (Amoroso, et al., 
2016), over the entire course of the nPOD project. The ELISA assays have maintained a high 
level of specificity 99-100% for each analyte as well as good sensitivity 62-82% (Table 1 
[CW1]).  Additionally, the screening assay is confirmed with an orthogonal RIA, which is also 
the gold standard. Direct comparison of these two formats in autoantibody positive subjects 
with or without T1D reveals a majority concordance, yet there remain some differences (Fig 3 
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[CW1]). This is attributed speculatively to differences in epitopes or simply false positives. 
Nonetheless, the nPOD program has decided to maintain the RIA as the gold standard and as 
the confirmatory assay. 
 Finally, we have access to the screening assay serum sample as well as the serum 
sample obtained at the time of recovery of the organs for research (Campbell-Thompson, et 
al., 2012a). The amount of time that has elapsed between screening and recovery varies form 
hours to days.  We found in two cases that the screening serum sample was positive but the 
recovery sample was negative in both the ELISA and RIA autoantibody assays (Fig 4 [CW1]). 
This we attributed to management of the patient in the ICU with drugs, fluids and transfusions 
and concluded that these parameters could potentially impact results of the autoantibody 
analyses. In the majority of cases we have confirmed autoantibody screening results and have 
obtained high quality human pancreas tissue for study by the wider diabetes community. The 
ELISA format is suitable for these screening efforts. 
 
4.2 The insulitis lesion in humans reveals the heterogeneity of type 1 diabetes. 
 
The nPOD project opens up studies of the human T1D condition in the modern era; however, 
not to be overlooked are earlier efforts (Foulis and Stewart, 1984; Gepts, 1965; Richardson, et 
al., 2014). These efforts aided in establishing T1D as a condition of infiltrating leukocytes and 
together with the discovery of autoantibodies (Bottazzo, et al., 1974) and HLA (Cahill and 
McDevitt, 1981) associations, suggested an autoimmune origin for this disease. These earlier 
efforts were performed on cadaveric post mortem subjects whereas nPOD obtains transplant 
grade tissues (Campbell-Thompson, et al., 2012a). Additionally, nPOD enables study of 
tissues available from autoantibody positive subjects without T1D, who may have been pre-
diabetic. Some pressing questions surround the extent of insulitis throughout the natural 
history of the disease; therefore, our aims for this project were to conduct an extensive survey 
of the nPOD tissues for insulitis and β-cell mass ((Campbell-Thompson, et al., 2016a) [CW 2]). 
 We first determined insulitis frequency (islets with insulitis / total islets) as described 
elsewhere (Campbell-Thompson, et al., 2013). A total of 80 organ donors with T1D, 18 
autoantibody positive donors without diabetes and 61 autoantibody negative control donors 
were evaluated (Supplementary Table 1 [CW2]). Of these 23% of T1D and 11% of the 
autoantibody positive without T1D had evidence of insulitis while none of the autoantibody 
negative donors had insulitis (Table 1 [CW2]).  
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 We noted variability in the lobular distribution of both insulin positive islets and insulitic 
islets within the T1D cohort (Fig 1 [CW 2]); furthermore, the number of CD3+ cells per islet 
varied in a given donor (Fig 2 and Supplementary Fig 2 [CW 2]). Of interest in the autoantibody 
positive subjects, insulitis was restricted to primarily insulin containing islets (Supplementary 
Fig 1 [CW2]), while all 18 T1D donors with insulitis had insulin containing islets in at least one 
section.  
 Not unexpectedly prevalence of insulitis correlated with T1D duration in those with the 
disease, but not with age of onset or age at demise (Fig 3 A-C [CW2]). Additionally, no 
correlations of insulitis with body mass index (BMI), ethnicity or sex could be found 
(Supplementary Table 3 [CW 2]. As far as hospital management, length of stay did not 
correlate with insulitis, but there was a significantly higher proportion of donors with insulitis 
who had DKA during the course of their management (47% vs. 7%, p=0.04) [CW2]. The high 
risk HLA genotypes DR3/DR4 were noted to occur with higher frequency in the T1D donors 
compared to both autoantibody negative and positive donors without diabetes. This is not 
unexpected, and no relationship could be found with insulitis (Supplementary Table 3 [CW2]). 
Interestingly, one T1D subject had the protective HLA DQ06 allele and had insulitis. The two 
autoantibody positive donors without diabetes with insulitis had intermediate to higher risk HLA 
DR7/18 DQ02/04 and DR4/- DQ8/-, respectively. 
 In evaluating the characteristics of the infiltrating leukocytes by multi-color 
immunofluorescence (Fig 4 [CW2]), we found that the lymphoid series of T and B cells (CD45+, 
CD3+, CD4+, CD8+ and CD20+) were proportionate to each other and proportionate to the 
insulitis frequency (Fig 5 [CW2]). There was, however, variability when comparing islet to islet 
and donor to donor, highlighting the heterogeneity of these infiltrates. Additionally, the myeloid 
series of cells (CD68+ and CD11c+) did not correlate with insulitis frequency (Supplementary 
Fig 4 and Supplementary Table 4 [CW2]). 
 Since pancreatic weight data were available and we had stained for insulin and 
glucagon, we could estimate α- and β- cell mass. Similar to our previous findings (Campbell-
Thompson, et al., 2016b), the weight of the pancreas was decreased in T1D subjects relative 
to growth (age) and compared to those without T1D (Fig 6 and supplementary Fig 5 [CW2]). 
Not unexpectedly, β-cell mass was decreased in donors with T1D compared to those without 
T1D; however, within the T1D donor group those with insulitis had higher β-cell mass than 
those without insulitis (Fig 6 [CW 2]). We found no differences in α-cell mass across all donor 
groups tested (Fig 6D and E [CW2]). 
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4.3 Complement deposition in the human pancreas is not specific to islet 
vasculature. 
 
While the general consensus is that autoantibodies are excellent biomarkers of T1D, they are 
not considered pathogenic (Ziegler, et al., 1993). However, given the observed relative paucity 
of insulitis we decided to investigate aspects of humoral immunity in human pancreas of T1D 
donors. We took the approach used by the transplant community (Jen, et al., 2012) with the 
goal of investigating antibody-mediated complement activation ((Rowe, et al., 2013) [CW 3]). 
Specifically, we immunostained C4d in pancreatic cryosections from 11 T1D, 16 autoantibody 
positive without T1D, 11 autoantibody negative without diabetes, and 7 T2D subjects.  
 In all of these groups if C4d staining was detected, it was either on the endothelium of 
small blood vessels or on the endothelium/extracellular matrix of larger vessels or adventitia 
of ductal structures (Fig 1A [CW 3]). Total C4d was expressed as percentage pixels positive 
using image analysis software. This was independently confirmed by an expert pathologist, 
and the Spearman rank correlation between the automated pixel count versus the pathologist 
rank was r=0.86, p<0.001. A significant difference between the groups was found, with T1D 
subjects having more C4d deposition (Fig 1B [CW 3]). Furthermore, ROC analysis yielded a 
sensitivity of 81.8% and specificity of 94.4% in discriminating autoimmune diabetes from T2D 
and no diabetes (Fig 1B [CW 3]).  
 We observed lower mean C4d deposition in T1D subjects with insulitis (17.8 ± 4.3%, 
n=5) than those without insulitis (31.4 ± 5.7%, n=6); however, this did not reach statistical 
significance (p=0.08). While as a group the autoantibody positive without diabetes did not differ 
from either the T2D or autoantibody negative without diabetes, (Fig 1B [CW 3]) there were two 
autoantibody positive subjects with higher C4d deposition one of whom also had insulitis. 
There were no correlations with either a) frequency or b) type of autoantibodies for any of the 
studied groups nor any hospital management metadata (ICU time, downtime or cause of death) 
[CW 3]. 
 
4.4 The pancreas of individuals with type 1 diabetes shows progressive loss of 
insulin, but proinsulin persists 
 
The standard model of T1D (Eisenbarth, 1986) posits that a steady decline in β-cell mass over 
time eventually leads to clinical diagnosis of diabetes with loss of glucose homeostasis. Our 
aims in this project were to investigate the endocrine hormones and processing pathways 
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throughout the natural history of T1D ((Wasserfall, et al., 2017) [CW 4]). A total of 106 pancreas 
samples from organ donors comprising 50 controls without diabetes, 16 autoantibody positive 
without diabetes, and 40 T1D subjects were used in this study (Table 1, [CW 4]).  
 We performed multicolor immunofluorescence (IF) for proinsulin, insulin and glucagon 
(Fig 1 [CW 4]) on representative formalin fixed paraffin embedded (FFPE) pancreas sections 
from control and T1D subjects with 1, 2 and 7 years of disease duration. The control sections 
not only revealed abundant islets with proinsulin, insulin and glucagon staining (Fig 1A, F, K 
and P [CW4]) but also, random single cells in the exocrine regions also staining for these 
hormones (Fig 1A inset [CW 4]). In the case of T1D with varying durations, these sections 
reveal heterogeneity in progression of disease with glucagon dominant islets along with single 
cells positive for each hormone individually (Fig 1 [CW4]). 
 We followed this with acid-ethanol extractions of thick (3x50μm) cryopreserved 
pancreatic sections from 31 controls, 16 autoantibody positive without diabetes, and 24 T1D 
subjects. We measured proinsulin, insulin, C-peptide and glucagon by ELISA and islet amyloid 
polypeptide (IAPP) by Luminex magnetic bead based assays. Within the autoantibody positive 
group, there were 12 single and 4 multiple autoantibody positive subjects (Table S2 [CW 4]). 
The extracted proinsulin, C-peptide and insulin levels were not related to frequency of 
autoantibodies and therefore, these subjects were grouped together and analyzed as an 
autoantibody positive cohort.   
 In the T1D group 5/24 individuals had extracted insulin levels similar to control levels, 
but 17/24 samples were at the lower end of the standard curve, and a further 2/24 had no 
detectable insulin. By comparison, the controls and autoantibody positive without diabetes 
tissues had significantly higher levels of insulin (Fig 2A [CW4]). Proinsulin levels, however, 
were detectable in all extracts from each group including the T1D subjects. The median 
proinsulin levels were significantly lower in the T1D group relative to controls but still 
measurable (Fig 2B [CW]). C-peptide levels were significantly lower in T1D pancreas 
extractions compared to control and autoantibody positive samples (Fig 2C, [CW 4]). Taken 
together, when analyzing a ratio of proinsulin to insulin or proinsulin to C-peptide, a significant 
difference was revealed between T1D and controls or autoantibody positive subjects (Fig S1B-
C [CW 4]).  
 IAPP is co-secreted with insulin from the β-cells. The levels of this peptide hormone 
were undetectable in 13/18 T1D samples and dramatically reduced in the remaining 5 subjects 
relative to both control and autoantibody positive samples (Fig 2D [CW4]). In contrast glucagon 
was present in similar levels between T1D and control subjects (Fig 2E [CW4]). An analysis of 
	 	
	24	
proinsulin with insulin showed a correlation in controls but not T1D or autoantibody positive 
without diabetes subjects for these two analytes (Fig 2F-H [CW4]). 
 We next assayed by RT-qPCR expression levels of heterogeneous nuclear RNA 
(hnRNA) for insulin (INS), calmodulin 1 (CALM1), serine protease inhibitor Kazal-type 1 
(SPINK1), cyclophilin A (PPIA) and chymotrypsin C (CTRC). Similarly, mRNA for INS, insulin-
insulin like growth factor 2 read through (INS-IGF2), IAPP, glucagon (GCG) and somatostatin 
(SST) were measured. Consistent with the protein levels of proinsulin, we found low but 
reproducible levels of insulin mRNA in T1D pancreas (Fig 2I [CW 4]); however, the hnRNA for 
INS was not detectable in most T1D samples (Fig 2J [CW4]). The hnRNA for CALM1, SPINK1, 
PPIA and CTRC were present and comparable between control and T1D pancreas samples 
(Fig S2 [CW4]). The INS-IGF2 read through mRNA was largely undetectable in T1D subjects 
(Fig 2K [CW 4]). Taken together, this suggests the insulin promoter is largely silent in T1D. 
The mRNA expression levels for IAPP were, for the most part, very low or undetectable in T1D 
subjects while control pancreas had detectable IAPP in all cases, which corroborates the IAPP 
protein data. (Fig 2D and L [CW4]). Data for GCG and SST mRNA show that the levels for 
these two analytes are similar between control and T1D samples (Fig 2M-N [CW 4]). 
 To better understand the location of and distribution of insulin and glucagon positive 
cells and based on previous observations, we performed a semi-quantitative analysis of these 
hormones in a subset of controls (n=5), short duration T1D (0-7 years, n=5) and longer duration 
T1D (8-35 years, n=6).  
 Representative images of a control and two T1D subjects (one with 7 years of duration 
and one with 35 years of duration) double stained for insulin and glucagon (Fig 3A-E and insets 
[CW 4]) showed the distribution of islets and hormone positive single cells in control pancreas 
and through the progression of disease. Of note, T1D subjects have a lobular distribution of 
islets that are termed pseudoatrophic, meaning glucagon positive in the absence of insulin, as 
also shown in ((Campbell-Thompson, et al., 2016a) [CW3]). Both control and T1D subjects 
had single cells staining for insulin protein and also INS mRNA as exemplified by INS in situ 
hybridization (ISH) stained sections (Fig 3F-J [CW4]).  
 The presence of insulin within islet cells was diminished in T1D samples from short 
duration compared to controls and absent in longer duration T1D subjects (Fig 3K [CW 4]). 
This was additionally supported by increasing counts of pseudo-atrophic (insulin+glucagon-) 
islets, with a concomitant decrease in the counts of double positive (insulin+glucagon+) islets 
(Fig 3L-M [CW4]) with increasing duration of disease. We also observed insulin positive cells 
in small clusters (2-5 cells) or as single cells in the acinar areas. These were abundant in the 
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control pancreata but also present, albeit in reduced numbers, in both short and long duration 
T1D samples (Fig 3N-O [CW4]). 
 We next investigated whether the enzymes involved in the processing of proinsulin 
were altered in T1D pancreata. To that end mRNA for PSCK1 was reduced in T1D samples 
relative to controls, while mRNA for PCSK2 and CPE were not different between the groups 
(Fig 3P-R [CW4]). Finally, we measured IFNγ, IL-1β and TNFα expression by RT-qPCR in 
control and T1D pancreata (Fig S4 [CW 4]). We found that IFNγ was undetectable in all cases, 
but IL-1β was present in similar levels between the two groups (Fig S4A [CW4]). TNFα was 
not detectable in approximately one third of the T1D and half of the control samples (Fig S4B 
[CW 4]). 
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5 Discussion 
 
5.1 Even with a low prevalence disease such as T1D, it is possible to screen organ 
donors for the presence of disease specific autoantibodies. 
 
Our experience has been that with practice and refining the cutoffs for positivity, adjustments 
to the assay preparations and training of screening laboratories, we have been able to detect 
the frequency of autoantibodies in the published literature. Meaning for any given single 
autoantibody, we have about 3% of the screens being positive and approximately 0.2% of 
samples are positive for multiple (i.e., two or more) autoantibodies [CW 1]. This push for a 
higher threshold also means we have a higher specificity for nPOD borne out in the IASP 
proficiency challenge testing, where we have consistently scored at around 100% specificity. 
While not usual for a screening program to emphasize specificity, we have done so for ethical 
(not removing false positive organs from transplant pool) and logistical reasons in terms of 
manpower and cost to recover organs. We currently have no way of knowing for sure that 
these organs were truly from a subject that would ultimately progress to T1D, but together with 
high-risk HLA and multiple autoantibody positive status, we are reasonably certain that these 
are true pre-T1D cases. This is consistent with multiple studies using these tissues showing 
differences between the autoantibody positive cases and control cases. For example changes 
in proinsulin to insulin ratios in autoantibody positive cases (Rodriguez-Calvo, et al., 2017), 
differential proteomic changes in autoantibody positive pancreas (Burch, et al., 2015), and 
others (Kaddis, et al., 2015). It is therefore reasonable to speculate that future studies and 
increase in knowledge will allow us to better stratify these subjects. 
 The use of an orthogonal RIA for confirmation of these ELISA screening results has 
shown that the two assay formats were for the most part in agreement. The few discordant 
results are speculated to be epitope specific differences or format differences, but this remains 
unknown. Nonetheless, we have confidence in the overall ability to obtain true autoantibody 
positive organ donor samples for the nPOD program.  
 
5.2 Insulitis in the natural history of T1D 
 
The ability to analyze pancreas samples across the spectrum of pre-T1D, new onset T1D and 
established T1D is unique and an invaluable aspect of nPOD. Our study using standardized 
protocols, high quality tissue and access to the whole organ has allowed us to address insulitis 
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frequency, leukocyte subtypes, pancreatic weights and hence α- and β-cell mass. This we 
believe adds much to the collective understanding of cellular infiltrates in human T1D.  
 Firstly, we have agreement that insulitis occurs in 23% of our cases [CW 2] versus 21% 
in other studies (In't Veld, 2011). However, we found 100% insulitis in subjects with duration 
of less than one year and 19% in those with a duration greater than one year, while the 
published literature suggests 51% and 3%, respectively (In't Veld, 2011). We would note that 
given the marked heterogeneity in the insulitic lesion, perhaps one reason for this discrepancy 
is that nPOD has the whole pancreas with multiple blocks available and screened, while others 
have had smaller pieces of tissue to examine. We are also in agreement regarding the 
proportion of insulin-containing islets with insulitis (33%) versus 2% of those that do not contain 
insulin, when compared with the Foulis et al. study (Foulis, et al., 1986) where they found 
insulitis in 28-35% of insulin-containing versus 1-5% of insulin-absent islets. The notion of 
insulitis being present in an antigen specific manner and the presence of insulitis in insulin 
negative islets could imply other autoantigens (which have not been stained for in this case) 
such as GAD or IA-2 or in ongoing bystander type reactions, which will need to be addressed 
in future studies. 
 Secondly, we also found insulitis in 2 out of 5 autoantibody positive subjects without 
T1D and none of the single autoantibody positive subjects. The two subjects with insulitis both 
had the combination of GADA and IA-2A. This is consistent with a published study 
demonstrating insulitis in 2 out of 7 multiple autoantibody positive subjects (In't Veld, et al., 
2007). This is also further demonstration that the nPOD screening process is potentially finding 
true pre-T1D subjects.  
 Another finding of note was the similarities in leukocyte subtypes in both pre-T1D and 
diagnosed cases. We found that each insulitic islet was heterogeneous in ratios of various 
leukocyte subsets, but when compared to overall frequency of insulitis, each subtype in the 
lymphoid compartment increases linearly. This implies a broad immune response to both 
insulin containing and insulin deficient islets. This is similar to the findings of others (Bottazzo, 
et al., 1985; Coppieters, et al., 2012; Dotta, et al., 2007; Foulis, et al., 1986; Hanafusa and 
Imagawa, 2008; Hanninen, et al., 1992; In't Veld, et al., 2007; Itoh, et al., 1993; Leete, et al., 
2016; Richardson, et al., 2011; Somoza, et al., 1994); however, some have an emphasis on 
finding predominantly CD8+ and macrophage infiltrates. Whether this reflects differences in 
protocols and/or donor demographics remains to be seen. Once again our study has looked 
at this question with a greater number of sectional areas of the pancreas studied and at 
different stages of the disease process. More recently, studies have highlighted potential for 
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higher CD20+ B-lymphocyte infiltrate frequencies to potentially differentiate those with early 
onset T1D (Leete, et al., 2016).  
 Pancreatic mass was found to be significantly smaller in individuals with T1D 
independent of age or duration. While autoantibody positive individuals did not show this 
difference when compared to controls, this was in contrast to our previous smaller study of 
autoantibody positive subjects, where we did see a difference in pancreas size compared to 
controls; however, the notion of a smaller pancreas in T1D subjects continues to be upheld 
(Campbell-Thompson, et al., 2012b; Campbell-Thompson, et al., 2016b). Indeed, this has 
been noted before (Gaglia, et al., 2011; Goda, et al., 2001; Philippe, et al., 2011; Williams, et 
al., 2012) in living subjects. We hypothesize that since we don’t exactly know where 
autoantibody positive donors are in their potential progression/staging to T1D, that the question 
of pancreas volume will be best resolved by either an appropriate increase in the number of 
donors studied or in longitudinal radiological assessments of those at risk for and through onset 
of disease. 
 Since we had the whole organ along with pancreatic weights, we were able to provide 
a metric of α- and β-cell area and mass. Not surprisingly, β-cell area and mass are significantly 
reduced in T1D subjects. Also of note, the β-cell mass was higher in those with insulitis 
compared to those without, potentially implying an association of autoantigenic load or these 
sample reflecting an earlier stage in the process of infiltration. 
 
5.3 Complement deposition in the natural history of T1D 
 
In our study of C4d staining in the pancreas, the initial goal was to test an alternative potential 
mechanism of β-cell death [CW 3]. This was partly in response to the initial findings of lower 
than expected frequency of insulitis in T1D cases, but also in response to an earlier literature 
that had defined complement fixing ICA autoantibodies (Bottazzo, et al., 1980; Mustonen, et 
al., 1983).  However, we found that C4d deposition occurred throughout the pancreas in T1D 
subjects and in 2 autoantibody positive subjects, 1 of which also had insulitis. The distribution 
of C4d on mostly exocrine vasculature and extra-cellular matrix components does not implicate 
islets directly. We therefore cannot conclude that the observed C4d deposition was due to 
complement fixing ICAs. Future efforts should not only look directly at other aspects of 
complement biology but also must address what may be occurring in the exocrine pancreas, 
in terms of inflammation and the aforementioned smaller pancreas in T1D. 
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5.4 Presence of endocrine hormones in the natural history of T1D 
 
Our analysis of the endocrine parameters throughout the natural history of T1D led to several 
observations [CW 4]. Collectively, we noted the presence of proinsulin as protein in a large 
proportion of T1D pancreata, by both immunostaining and specific ELISA methodologies on 
cryopreserved samples and extracts. We also found mRNA for proinsulin by ISH and by RT-
qPCR, but mature insulin and C-peptide proteins were mostly undetectable. We interpret the 
finding of lower PCSK1 in T1D as one possible reason that we detect proinsulin in the near 
absence of insulin and C-peptide, which may imply partial processing in the maturation of these 
analytes. We also found near absence of IAPP and would note that a recently developed assay 
to measure pro-IAPP revealed a higher pro-IAPP to IAPP ratio in T1D with the authors 
concluding that the processing machinery may be impaired (Courtade, et al., 2017). Together 
these two observations are consistent with there being a defect in processing of both proinsulin 
and pro-IAPP since these utilize the same proconvertases and pathways (Alarcon, et al., 
2012). Another potential explanation could be rapid secretion of both pro-hormones, as has 
been described in T2D (Alarcon, et al., 2016), leaving minimal time to process, this would have 
to be tested functionally on live tissue. 
 Isolated islets from control and T1D organ donors have been tested for glucose 
responsiveness, so functional assays have been possible. However, we would note our other 
findings herein, namely that of single cells in the acinar regions testing positive for insulin. 
These single cells exist in abundance in control pancreata and progressively decrease in 
number with duration of T1D. Importantly, in longer duration T1D, islets are mostly depleted of 
insulin, but some of these single cells remain. In that light, isolating islets and testing them, will 
not capture the functionality of these single cells. Also, we do not have sufficient information 
on these hormone positive single cells to conclude whether these are de-differentiated cells 
(Accili, et al., 2016; Talchai, et al., 2012) or potentially stem cells (Moin, et al., 2017; van der 
Meulen, et al., 2017), and this will be pursued in future studies. 
 We also found similar levels by extraction and mRNA for glucagon consistent with our 
earlier [CW 2] observations on α-cell mass. The same was also true for levels of mRNA for 
somatastatin, but we have not formally quantified δ-cells. We did not find any significant 
differences in any of these endocrine compartments in autoantibody positive pancreas 
samples; this is in contrast to a recent observation of higher proinsulin by immunofluorescence 
staining in subjects at risk for T1D (Rodriguez-Calvo, et al., 2017). The immunostaining reagent 
antibodies used in these two studies may not be able to distinguish the various intermediate 
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forms of proinsulin, and this would have to be finally resolved by alternative assays 
(radiolabelling or mass spectrometry) to identify the various partially processed proinsulin 
molecules (Rhodes, et al., 1992).  
 Finally, we also found that hnRNA (unspliced nuclear RNA) for insulin was 
undetectable as was mRNA for the INS-IGF2 read-through product, and this coupled with INS 
mRNA being present we interpret as the insulin promoter being inactive with long lived INS 
mRNA explaining the persistence of proinsulin. It is possible that there is insufficient hnRNA 
for our detection especially if this is mostly in single cells rather than in islets. This remains 
unresolved and would be subject of future studies with functional access to live cells from the 
pancreas, as had been pioneered in mouse pancreas (Marciniak, et al., 2014; Speier, et al., 
2013).  
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6 Resume 
 
The study of human T1D as an autoimmune disease of the pancreas started, it could be 
argued, with the discovery of insulin using pancreatectomized animals. This followed a period 
of studies of insulin replacement refinements, improvements in technologies and studies in 
blood samples of metabolic and autoimmune phenomena. While animal models allowed end 
organ analysis, the study of human pancreas was severely limited in comparison to studies of 
peripheral blood. It is therefore fitting that what was learned from these peripheral blood studies 
allowed us to assemble, via nPOD, a human pancreas bank including samples from those 
deemed at higher risk for T1D by peripheral blood autoantibody analysis (Wasserfall, et al., 
2016) [CW 1]. 
 The main goal of my thesis was, with these samples in hand and still continuing to 
accrue, to address several fundamental questions in human T1D biology. Firstly my colleagues 
and I were able to study insulitis in autoantibody positive subjects and in those with a diagnosis 
of T1D (Campbell-Thompson, et al., 2016a) [CW 2].  Herein we found insulitis in 2 of 5 
autoantibody positive subjects’ pancreas samples, both having the combination of GADA and 
IA-2A. In pancreas samples from T1D donors with less than a year of disease duration, 100% 
had insulitis. While, in those with greater than one year of disease duration, 23% had insulitis. 
This implies that insulitis occurs closer to onset of disease and then wanes thereafter. This is 
in stark contrast to the NOD mouse model where insulitis occurs very early and in 100% of 
these inbred mice whether they progress to T1D or not. Also in stark contrast to the NOD, 
while β-cell mass was reduced in T1D pancreas samples it was not completely absent. We 
also confirmed findings of reduced overall mass of human T1D pancreas samples that are not 
explained by missing β-cells, which make up only a small fraction of the organ. This implicates 
loss of exocrine tissue in some manner that remains unresolved.  
 Next, we tested whether complement plays a potential role in T1D using C4d deposition 
as a marker of (auto)antibody mediated events (Rowe, et al., 2013) [CW 3]. Unexpectedly, we 
found that while there was increased C4d staining in T1D pancreas samples, the distribution 
implied potential exocrine inflammation and not necessarily islet specific events. Whether this 
is tied into the findings of smaller pancreata in T1D is an obvious question for future study. 
 In then compiling these notions together, I used a technique to extract proteins from 
whole frozen sections of pancreas and found persistence of proinsulin while insulin and C-
peptide levels were low to undetectable by ELISA in T1D samples (Wasserfall, et al., 2017) 
[CW 4]. In further teasing this apart, we discovered INS mRNA was present by ISH and RT-
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qPCR along with both proinsulin and insulin by immunohistochemistry. We also were able to 
semi-quantify the progression of T1D, by the loss of insulin in islets but the persistence of 
insulin positive single cells with longer disease duration. The PCSK1 enzyme was also reduced 
in T1D samples by RT-qPCR, suggesting a possible mechanism for incomplete processing of 
proinsulin into mature insulin and C-peptide. Resolving this pathway and addressing whether 
the single insulin positive cells can be rescued as a therapeutic option or whether they are 
dedifferentiating β-cells will be pursued in future endeavors.  
 In conclusion, my thesis work has demonstrated that insulitis appears closer to T1D 
onset, is evident at onset, and wanes after a year of duration. It is also true that not every islet 
is infiltrated, but those that are have T-, B-, dendritic cells and macrophages in a 
heterogeneous distribution. The loss of β-cells is lobular, and proinsulin can be found in T1D 
pancreata. Proinsulin, insulin and glucagon can be found in single cells long after the 
disappearance of β-cells within islet structures in T1D pancreas samples. The overall pancreas 
is smaller, and by deduction, this must be a loss of exocrine tissue since β-cells make up a 
tiny fraction of the overall mass. C4d is deposited in exocrine areas and others have found 
exocrine leukocytic infiltrates (Campbell-Thompson, et al., 2015; Rodriguez-Calvo, et al., 
2014). There is an older literature as well as emerging studies, including some from our group, 
corroborating findings of diminished exocrine secreted products and function (Frier, et al., 
1976; Kondrashova, et al., 2017; Lankisch, et al., 1982; Li, et al., 2017). Taken together, there 
appears to be involvement of the exocrine pancreas in T1D and it remains to be seen if this is 
part of the autoimmune process or in response to the loss of insulin (Campbell-Thompson, et 
al., 2015). 
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Summary [German] 
 
Die Studie des menschlichen T1D (Type 1 Diabetes), als eine Autoimmunerkrankung der 
Bauchspeicheldrüse, könnte man mit der Entdeckung von Insulin unter Verwendung von 
pankreatectomisierten Tieren argumentieren. Es folgten Studien zur Verfeinerung des 
Insulinersatzes, Verbesserung der Technologien und zur Untersuchung von Stoffwechsel- und 
Autoimmunphänomenen in Blutproben. Während Tiermodelle eine Endorgananalyse 
erlaubten, war die Untersuchung der menschlichen Bauchspeicheldrüse im Vergleich zu 
Studien mit peripherem Blut stark eingeschränkt. Anhand der so genannten peripheren 
Blutstudien, die nPOD (Network for Pancreatic Organ Donors with Diabetes), konnte eine 
menschliche Bauchspeicheldrüsenbank mit Proben von Personen zusammenzustellt werden, 
die durch die Analyse peripherer Blut-Autoantikörper (Wasserfall, et al., 2016) für T1D als 
risikoreich eingestuft wurde [CW 1]. 
Das Hauptziel meiner Dissertation bestand darin, mit diesen noch immer ansteigenden 
Proben, einige grundlegende Fragen der menschlichen T1D-Biologie zu beantworten. Zuerst 
konnten meine Kollegen und ich Insulitis bei Autoantikörper-positiven Probanden und bei 
Patienten mit T1D-Diagnose (Campbell-Thompson, et al., 2016a) studieren [CW 2].  Dabei 
fanden wir in 2 von 5 Pankreasproben Insulitis von Autoantikörper-positiven Probanden, beide 
mit der Kombination GADA und IA-2A. In Pankreasproben von T1D-Spendern mit weniger als 
einem Jahr Krankheitsdauer hatten 100% der Patienten eine Insulitis. Während, in denen mit 
mehr als einem Jahr Krankheitsdauer, 23% der Insulitis aufzeigten. Dies impliziert, dass die 
Insulitis vorwiegend zum Krankheitsbeginn auftritt und danach abnimmt. Das steht im 
extremen Gegensatz zum NOD-Mausmodell, bei dem Insulitis sehr früh auftritt und bei 100% 
der Inzuchtmäuse, unabhängig davon, ob sie T1D entwickeln oder nicht. Auch im Gegensatz 
zum NOD, während β-Zellmasse in T1D-Pankreasproben reduziert wurde, fehlte es nicht 
ganz. Wir bestätigten ebenfalls die Ergebnisse einer reduzierten Gesamtmasse menschlicher 
T1D-Pankreasproben, die nicht durch fehlende β-Zellen erklärt werden, da die nur einen 
kleinen Teil des Organs ausmachen. Dies impliziert den Verlust von exokrinem Gewebe in 
einer Art und Weise, die bis heute ungeklärt bleibt.  
Weiterhin haben wir getestet, ob Komplement eine potenzielle Rolle in T1D spielt, indem die 
C4d-Deposition als Marker für (Auto) Antikörpervermittelte Ereignisse verwendet wurde 
(Rowe, et al., 2013) [CW 3]. Unerwarteterweise fanden wir heraus, dass es erhöhte C4d 
Antikörperfärbung in T1D Pankreasproben gab. Dies implizierte die Verteilung potentieller 
exokriner Entzündungen und nicht unbedingt Insel-spezifische Ereignisse. Ob dies mit den 
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Befunden der kleineren Bauchspeicheldrüse in T1D zusammenhängt, ist eine naheliegende 
Frage für zukünftige Studien. 
Bei der Zusammenstellung dieser Begriffe verwendete ich eine Technik, um Proteine 
aus gefrorenen Abschnitten der Bauchspeicheldrüse zu extrahieren und fand die Persistenz 
von Proinsulin, während die Insulin- und C-Peptid-Konzentrationen niedrig bis nicht 
nachweisbar durch ELISA in T1D-Proben waren (Wasserfall, et al., 2017) [CW 4]. Weiterhin 
konnten wir zeigen, dass INS mRNA durch ISH und RT-qPCR zusammen mit Proinsulin und 
Insulin durch Immunhistochemie anwesend war. Wir waren ebenfalls in der Lage, die 
Progression von T1D semi-quantifizieren, durch den Verlust von Insulin in Inselchen, sondern 
die Persistenz von Insulin-positiven Einzelzellen mit längerer Krankheitsdauer. Das Enzym 
PCSK1 wurde außerdem in T1D-Proben durch RT-qPCR reduziert, was auf einen möglichen 
Mechanismus für die unvollständige Verarbeitung von Proinsulin zu reifem Insulin und C-
Peptid hindeutet. Die Aufklärung dieses Prozesses und die Frage, ob die einzelnen 
insulinpositiven Zellen als therapeutische Option gerettet werden können oder ob sie die Zellen 
von β dedifferenzieren, werden in Zukunft weiterverfolgt.  
Zusammenfassend hat meine These gezeigt hat, dass Insulitis näher am T1D-Einstieg 
erscheint, dass sie zu Beginn offensichtlich ist und nach einem Jahr nachlässt. Es ist zudem 
nachgewiesen, dass nicht jede Insel infiltriert wird, sondern diejenigen, die T-, B-, dendritische 
Zellen und Makrophagen in einer heterogenen Verteilung haben. Der Verlust von β-Zellen ist 
lobulär, und Proinsulin kann in T1D Pankreas gefunden werden. Proinsulin, Insulin und 
Glukagon sind in Einzelzellen zu finden, lange nach dem Verschwinden von β-Zellen innerhalb 
von Inselstrukturen in T1D-Pankreasproben. Die gesamte Bauchspeicheldrüse ist kleiner, und 
durch Abzug muss dies ein Verlust an exokrinem Gewebe sein, da β-Zellen einen winzigen 
Bruchteil der Gesamtmasse ausmachen. C4d wird in exokrinen Bereichen deponiert und 
andere haben exokrine Leukozyteninfiltrate gefunden (Campbell-Thompson, et al., 2015; 
Rodriguez-Calvo, et al., 2014). Es gibt zurückliegende sowie aktuelle Studien, darunter einige 
aus unserer Gruppe, die die Ergebnisse verminderter exokriner Sekretprodukte und 
Funktionen bestätigen (Frier, et al., 1976; Kondrashova, et al., 2017; Lankisch, et al., 1982; Li, 
et al., 2017). Hypotetisch ist eine Beteiligung der exokrinen Bauchspeicheldrüse an T1D 
möglich, und es bleibt abzuwarten, ob dies ein Teil des Autoimmunprozesses ist oder als 
Reaktion auf den Verlust von Insulin (Campbell-Thompson, et al., 2015). 
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